Smart Dividend Portfolio Edition #76: Enduring Dividends
1
Dear Investor,
Welcome to the 76th edition of TipRanks’ Smart Dividend Portfolio & Newsletter.
1
1
Market-Moving News: Sep 01, 2025
Stocks closed the week in the red as Friday’s sell-off nudged the indexes down from record-high territory. The Dow Jones Industrial Average (DJIA) was down 0.19%, while the S&P 500 (SPX) logged a 0.10% weekly loss. The tech large-cap benchmark Nasdaq-100 (NDX) fell 0.35%, weighed down by a sell-off in Nvidia (NVDA) and other AI names, along with broad semiconductor stocks.
Markets logged another turbulent week, moving between new highs and risk aversion. The S&P 500 reached intraday and closing records Tuesday through Thursday, but Friday brought an abrupt end to the party spurred by optimism over impending rate cuts. Stocks that led indexes higher earlier – tech megacaps, semiconductors, and cyclicals – sold off. This resulted in a softer performance to conclude the week, but the S&P 500 and the Dow still managed to lock in a fourth straight month of gains, while the Nasdaq rose for the fifth month in a row in August.
Still, weakness going into the long weekend – with markets closed on Monday for Labor Day – may stick around for a while, coming right before what is perceived as the worst month in the year for stocks. Historically, September trading has been punctured by both institutional investors rebalancing their portfolios and retail trading reaching its annual low, while corporations are forced to cool their buybacks before the next earnings season.
While “past performance is not indicative of future results,” options market positioning shows traders are already getting more cautious in the near-term. And who can blame them? While quarterly rebalancing and buyback freezes are quarterly constants, individual investors are a relatively new force on the markets, with their influence roughly tripling from the pre-pandemic era.
Retail investors now command about a third of total trading volumes in U.S. markets, compared with around 10% in 2018. So, when retail investors return from holidays and reassess positions, with portfolio rebalancing and profit-taking on the surge, this influences the broad markets three times more than in the past. Add multiple all-time highs to the picture – led by a relatively narrow set of stocks with high valuations – and you’ve got a recipe for volatility.
With the earnings season now officially locked in following Nvidia’s earnings release, economic data is retaking markets’ attention. The July PCE inflation report did little to shake the widespread September rate-cut expectations, as both headline and core PCE came in line with expectations and confirmed only a modest increase from previous months. The print confirmed that tariffs have yet to meaningfully filter into consumer prices, despite a recent increase in producer inflation.
Bets on a September cut grew sharply after Fed Chair Jerome Powell signaled a more dovish stance at Jackson Hole, citing recent cooling in the labor market. Policymakers held rates steady this year, citing worries that Trump’s higher tariffs could rekindle inflation – but the gradual weakening of one of their two mandates, jobs, seems to have tilted the scales.
Incoming data continued to muddy the picture for the central bank. The second GDP growth estimate indicated that the economy expanded at a 3.3% annualized pace in the second quarter, above the initial estimate of 3% growth. However, economists expect that slowing job growth – acknowledged by Powell in his remarks – won’t be able to support the fast economic expansion for much longer, adding fuel to rate-cut calls even though inflation remains a notable risk.
While consumer spending rose in July by the most in four months, August’s consumer sentiment index declined more than expected, and the consumer expectations component dropped to its lowest since May. Moreover, both 1-year and 5-year inflation expectations inched up in August, reflecting continued household worries – despite a second month in a row of strong increases in personal incomes.
Still, analysts overwhelmingly predict a 25 bps rate cut barring a strong upward surprise in the upcoming unemployment report, which will be one of the key factors determining the Fed’s easing pace this year – and likely next.
1
1
1
This Week’s Quality Dividend Stock Idea
Medtronic (MDT) is a global leader in medical technology, providing innovative therapies and solutions that address chronic diseases and improve patient outcomes. With a diverse portfolio spanning cardiovascular, surgical, neurological, and diabetes care, the company serves healthcare providers and patients worldwide. Leveraging decades of expertise and a strong global footprint, Medtronic emphasizes innovation, patient-centric care, and long-term value creation to strengthen its leadership in the healthcare industry.
1
Growth Journey
Medtronic’s story began in 1949, when Earl Bakken and Palmer Hermundslie founded the company in a Minneapolis garage, repairing medical equipment. A turning point came in 1957 with the invention of the first battery-powered, wearable pacemaker, a breakthrough that established the company as a leader in cardiac care. Over the following decades, the company expanded into implantable devices and broadened its expertise in vascular, neurological, and diabetes therapies, steadily building a reputation for innovation in chronic disease management.
The 1980s and 1990s marked rapid growth through acquisitions and international expansion, as Medtronic strengthened its cardiovascular business and diversified into neuromodulation and spinal therapies. This approach of pairing internal innovation with strategic deals enabled MDT to build a comprehensive portfolio and extend its global reach.
Over the past decade, Medtronic has actively reshaped its portfolio through acquisitions and divestitures, positioning itself for stronger earnings growth. Its most transformative move came in 2015 with the $43 billion acquisition of Covidien, an Ireland-based medical device maker, one of the largest transactions in medtech history. The deal expanded Medtronic’s product portfolio and global footprint, while smaller acquisitions that year – such as Aircraft Medical, Lazarus Effect, Medina Medical, and Twelve – added advanced capabilities in video intubation, stroke treatment, cerebral aneurysm devices, and mitral valve replacement.
In 2018, Medtronic entered robotic-assisted surgery through its purchase of Mazor Robotics, followed by Titan Spine and EPIX Therapeutics in 2019, which enhanced its spine and cardiac offerings. By 2020, acquisitions of Digital Surgery, Medicrea, and Companion Medical extended its presence in AI-powered surgical platforms, personalized spinal implants, and connected insulin delivery. The company broadened into ear, nose, and throat devices with its 2021 acquisition of Intersect ENT, and strengthened its cardiovascular position in 2022 with Affera and CathWorks, adding new technologies in arrhythmia management and cardiovascular imaging.
Alongside this expansion, Medtronic has streamlined its portfolio by divesting non-core businesses. In 2017, it sold Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency to Cardinal Health for $6.1 billion. More recently, the company announced plans to spin off its patient monitoring and respiratory interventions segments in 2022 and its diabetes unit in 2025, which contributed about 8% of revenue in the fiscal first quarter. The planned diabetes spin-off, expected within 15 months, is designed to be EPS accretive, adding roughly 50 basis points to gross margin and 100 basis points to operating margin. The new standalone company, named MiniMed will retain its innovation pipeline and global momentum, positioning it as a leader in diabetes technology while unlocking shareholder value.
Together, these portfolio moves reflect Medtronic’s strategic focus on higher-growth areas such as cardiovascular care, neuroscience, and surgical innovation. By concentrating on markets where scale and technology create competitive advantage, the company has strengthened its ability to drive innovation, improve agility, and sustain long-term earnings growth. Today, the company’s ~95,000 employees across 150 countries serve more than 78 million patients, addressing over 70 health conditions worldwide.
Medtronic, with a market capitalization of nearly $119 billion and trailing twelve-month revenues of nearly $34 billion, is listed at #497 on the 2025 Fortune 500 list.
1
Precision Care
Medtronic’s business model is built on a diversified portfolio of medical devices and therapies that address chronic diseases across four major operating segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. This breadth, combined with a strong global footprint gives the company resilience and multiple avenues for growth.
The Cardiovascular portfolio remains Medtronic’s largest business and the leading driver of earnings. In the first quarter of fiscal 2026, the segment generated $3.3 billion in revenue, up 9.3% year-over-year (7% organic). This accounted for 38.3% of total company revenue. The segment covers therapies for heart rhythm disorders, heart failure, structural heart and aortic conditions, and coronary and vascular diseases.
Growth in the quarter was led by a nearly 50% surge in Cardiac Ablation Solutions, fueled by the rapid rollout of Medtronic’s pulsed field ablation (PFA) technologies – PulseSelect, Sphere-9, and Affera. Unlike conventional methods, PFA uses non-thermal energy to remove cardiac tissue in atrial fibrillation (AFib), reducing risks of collateral damage. Recent FDA approvals and strong physician feedback are driving adoption, and its mapping systems are scaling rapidly. With the global PFA market projected to exceed $11 billion and grow more than 25% annually, Medtronic is well-positioned to emerge as a leader in this transformative category.
The Structural Heart division also delivered solid results, rising 6% on strength from the Evolut FX+ transcatheter aortic valve replacement (TAVR) system. The device, which improves coronary access, is both CE marked in Europe (conforming to EU regulatory requirements) and FDA-approved in the U.S. Demand accelerated after the company’s competitor, Boston Scientific, exited part of the TAVR market, enabling Medtronic to capture additional market share.
Cardiac Rhythm Management (CRM) grew 3%, supported by strong demand for new defibrillation devices. The Aurora EV-ICD, an extravascular implantable cardioverter-defibrillator, surged 83%, while pacing therapies advanced 3%, led by a 14% increase in Micra leadless pacemakers. Peripheral Vascular Therapies also made progress, with the launch of the Contego portfolio in Q2 and upcoming commercialization of Liberant H2 for stroke protection and vascular disease. The company is further expanding its reach through partnerships that combine the company’s stent and embolic protection technology.
Overall, Cardiovascular remains a “core right-to-win” business for the company. Its leadership in emerging areas such as PFA and TAVR, coupled with ongoing innovation in CRM and vascular therapies, positions the company to capture share in high-growth areas like atrial fibrillation ablation and transcatheter valve therapy.
The Neuroscience segment covers spinal and cranial technologies, specialty therapies for stroke, ENT, and bladder disorders, and neuromodulation devices that stimulate the spinal cord and brain. This business delivered $2.4 billion in revenue, up 4.3% (3.1% organic). Growth was led by advances in spine, neurosurgery, and neuromodulation, offset by transitional challenges in Pelvic Health and Neurovascular. Cranial & Spinal Technologies grew at a mid-single-digit pace, supported by 5% growth in U.S. Core Spine and 8% in Neurosurgery. Hospitals increasingly adopted the AiBLE surgical ecosystem, which integrates implants, robotics (Mazor), imaging (O-arm), powered instruments (Midas Rex), and navigation (StealthStation) for enhanced surgical precision. Capital equipment sales rose at double-digit rates, reflecting strong demand.
Neuromodulation advanced 9%, led by 10% growth in Pain Stimulation. In the U.S., spinal cord stimulation increased by 11%, driven by the Inceptiv closed-loop stimulator, which adjusts pain therapy in real-time. Brain Modulation grew at a high-single-digit pace, with strong adoption of the BrainSense adaptive DBS system across the U.S., Europe, and Japan. BrainSense allows physicians to fine-tune stimulation for conditions such as Parkinson’s disease, while new MRI labeling and flexible surgical options expanded its appeal.
By contrast, Specialty Therapies underperformed, with flat Pelvic Health sales amid reorganization and pending FDA approval of a tibial neuromodulation device for bladder control, though legacy InterStim devices held up internationally. Neurovascular also faced pressure from China’s volume-based procurement (VBP) program – designed to lower costs through bulk purchasing – and recalls of certain products, including the Pipeline Vantage flow diverter. Despite these challenges, the Pipeline Shield remains Medtronic’s global flagship, and upcoming carotid and hemorrhagic therapy launches are expected to reignite growth.
Overall, the Neuroscience business performance is expected to improve in the second half as new product launches in Pelvic Health and Neurovascular ramp. With a strong pipeline and advanced surgical platforms, the company is well-positioned for renewed growth in neurosurgery and neurostimulation.
1
Innovative Surge
Medtronic’s Medical Surgical Portfolio includes the Surgical & Endoscopy and Acute Care & Monitoring divisions. Surgical & Endoscopy develops advanced stapling, vessel sealing, wound closure, electrosurgery, and gynecology devices, as well as hernia repair implants and minimally invasive GI diagnostics and therapies. AI-powered surgical video and analytics platforms and robotic-assisted systems such as Hugo are central to growth. Acute Care & Monitoring provides patient monitoring and airway management solutions and showed a steady performance in the fiscal first quarter.
In fiscal Q1, Medical Surgical generated $2.08 billion in revenue, up 4.4% year over year (2.4% organic). Growth in the surgical business was tempered by fewer U.S. bariatric procedures and a market shift toward robotic platforms as hospitals and surgeons increasingly adopt minimally invasive approaches. Internationally, however, volumes expanded. Advanced Energy performed well, supported by the CE mark approval of Hugo for LigaSure integration in gynecologic, general, and urologic surgeries across Europe. Hugo is now in use in more than 30 countries and is expected to launch in the U.S. in the second half of FY25, beginning with urology and expanding to other indications.
Overall, Medtronic’s MedSurg business grew at a high-single-digit rate internationally, with momentum in Western Europe, Japan, and emerging markets. Robotics and AI remain central to strategy, with expectations for stronger U.S. growth in the second half as Hugo and related capital equipment sales accelerate.
The Diabetes segment outpaced company growth in Q1, delivering 8% organic growth, led by international demand, product innovation, and progress toward the planned spin-off of the business.
International sales rose 11%, fueled by the MiniMed 780G insulin pump and the upcoming Simplera Sync continuous glucose monitor (CGM). The 780G now integrates Meal Detection™ technology and SmartGuard™ automation and can be paired with the FDA-approved Simplera Sync or the Guardian 4 sensor. Simplera Sync, a disposable no-fingerstick sensor with two-step insertion, will launch in the U.S. in fall 2025.
Simplera Sync is rolling out internationally, while the Instinct sensor, developed with Abbott, is expected soon and will connect with Medtronic’s insulin delivery platforms. The 780G is also close to securing U.S. approval for use in type 2 diabetes, opening a much larger market opportunity. Meanwhile, the MiniMed Flex pump, a smaller and user-friendly device, is slated for FDA submission by April 2026.
Medtronic is also sharpening its operating model. Efficiencies and lower costs of goods sold are freeing up capital for reinvestment in R&D – described by management as the “oxygen cycle,” where innovation fuels growth, which in turn funds further innovation. Tariff pressures remain capped at $185 million annually, while a centralized supply chain enhances agility.
In mid-2025, Elliott Management took a significant stake in Medtronic, becoming one of its largest shareholders. The move triggered governance changes aimed at driving growth and shareholder value. Two independent directors joined the board: John Groetelaars, former CEO of Hillrom and Dentsply Sirona, and Bill Jellison, former CFO of Stryker.
Two new committees were also created. The Growth Committee oversees portfolio management, capital allocation, and M&A, while the Operating Committee focuses on efficiencies, cost reduction, and supply chain simplification. Together, these steps strengthen oversight, accountability, and strategic discipline, aligning Medtronic with best practices seen among peers. A detailed Investor Day in mid-2026 will outline long-term targets and post-separation strategy.
Medtronic continues to face near-term pressures, including Affera supply ramp challenges, tariff headwinds, mix impacts from China’s value-based procurement, and the need to scale new platforms quickly. With Elliott’s oversight, management aims to translate reinvestment cycles into “durable earnings” growth.
1
Earnings Pulse
Over the past three years, Medtronic’s revenues have grown at a CAGR of 3.3% while its EPS has declined by 2.2% over the same period, reflecting the strain of inflation, supply chain disruptions, and rising operating costs. This divergence between sales growth and profit growth highlights the pressure on margins, even as demand for the company’s products remained resilient.
That backdrop made Medtronic’s first-quarter fiscal 2026 results particularly important. The company delivered revenue of $8.5 billion, up 8.4% year over year (4.8% organic), marking its 11th straight quarter of mid-single-digit organic growth. Adjusted EPS increased 2% to $1.26, with both revenue and earnings exceeding Wall Street expectations. Growth was fueled by strong demand for next-generation offerings such as pulsed field ablation systems, transcatheter heart valves, and advanced diabetes devices. Still, adjusted operating margin slipped 80 basis points to 23.6%, as Medtronic continued to reinvest heavily in R&D and commercial initiatives to strengthen its pipeline and accelerate product launches.
The balance sheet remains a source of strength. Medtronic reported nearly $91 billion in total assets and $48.1 billion in shareholders’ equity at the end of the quarter. Cash and investments stood at $8.1 billion, giving the company ample liquidity to support dividends and ongoing capital investment, while long-term debt of $26.2 billion kept net leverage at manageable levels. With a debt-to-equity ratio of 0.6, higher than the sector median due to its history of large acquisitions and global expansion, the company nonetheless retains strong credit quality, holding “A” and “A3” investment-grade ratings from S&P and Moody’s.
Looking ahead, Medtronic reaffirmed its fiscal 2026 revenue outlook of roughly 5% organic growth and raised its full-year EPS guidance to $5.63 at the midpoint, above consensus estimates. The company expects momentum to accelerate in the second half of FY26, driven by new regulatory approvals, broader adoption of recently launched products, and execution on cost initiatives. The updated forecast reflects easing tariff headwinds and early benefits from operational efficiencies. For the second quarter, EPS is projected at $1.31, in line with analyst expectations. Management continues to target high-single-digit EPS growth by fiscal 2027, supported by operating leverage, disciplined reinvestment, and a growing portfolio of innovative therapies.
1
Dividend Strength
Medtronic has built a strong track record of rewarding shareholders, underpinned by nearly five decades of uninterrupted dividend growth. As a Dividend Aristocrat, the company has increased its dividend for 48 consecutive years, delivering an average 6% annual raise over the past decade. Today, the company distributes about 77% of its adjusted earnings to shareholders, supporting a dividend yield of 3.03%, notably higher than the healthcare sector average. In FY25, the quarterly dividend of $0.70 per share translated into an annualized payout of $2.80, reflecting management’s commitment to stable returns through varied market cycles.
Alongside dividends, MDT has continued to return capital through share repurchases. Last year, it authorized a $5 billion buyback program, under which the company repurchased 1 million shares in the second quarter at an average price of $86.22. As of July 25, 2025, $2 billion remained available under this authorization, signaling further flexibility for shareholder distributions.
Cash generation remains a cornerstone of the company’s strategy. In the latest quarter, the company produced $1.1 billion in operating cash flow and $584 million in free cash flow, supported by disciplined spending and higher earnings. Capital expenditures totaled $504 million, reflecting ongoing investments in manufacturing and innovation. This steady free cash flow profile enables Medtronic to fund R&D, pursue strategic acquisitions, and sustain its shareholder return program, all while maintaining balance sheet strength.
Operationally, Medtronic continues to deliver competitive returns, with a 9.5% return on equity placing it among the top quartile of the industry. Its return on assets of 5.1% and return on investment of 7.2% also rank within the upper tier of its sector. However, stock performance has been more muted. Over the past year, Medtronic shares have risen modestly, reflecting sector headwinds and investor caution over growth visibility. While restructuring efforts and upcoming spinoffs have provided support, the stock has trailed broader healthcare peers.
From a valuation standpoint, Medtronic trades at a 3% and 9% discount to the sector median and at a more than 10% discount to its historical average on the basis of non-GAAP trailing and forward P/E ratios. On the basis of trailing and forward P/E and EV/EBITDA metrics, the company occupies a low-to-moderate valuation range compared to rivals such as Abbott Laboratories, Stryker, and Boston Scientific.
Despite this underperformance, analysts remain constructive on the stock, projecting upside of 7.6% on average, with some estimates pointing to potential gains of nearly 25%. Sentiment has been further buoyed by the disclosure that Elliott Management has taken a stake in the company. The activist investor’s involvement is seen as a potential catalyst for operational and strategic improvements, reinforcing the bullish case. Looking ahead, Medtronic’s confidence rests on accelerating growth, anchored by a strong pipeline of product launches, upcoming regulatory approvals, and the company’s proven ability to return capital consistently to shareholders.1
1
Investing Takeaway
For income-focused investors, Medtronic stands out as a reliable dividend payer with a long history of rewarding shareholders. The company’s nearly five-decade track record of uninterrupted dividend growth reflects both financial resilience and management’s commitment to consistent capital returns. Its strong free cash flow generation provides the foundation to sustain and grow payouts, even through market volatility. Beyond dividends, disciplined capital allocation, including selective buybacks, further underscores its shareholder-friendly approach. While near-term stock performance has been tempered by industry headwinds and restructuring, the company’s defensive qualities, diversified business, and innovation pipeline provide long-term support for steady distributions. For investors seeking stability with a dependable income stream, Medtronic’s dividend profile remains a compelling part of its investment case.
1
Dividend Investor Portfolio
1
Portfolio News
▣ Royalty Pharma agreed to acquire a royalty interest in Amgen’s (AMGN) lung cancer therapy Imdelltra, paying $885 million upfront, with an option to purchase additional royalties for up to $65 million, bringing the potential total to $950 million. Imdelltra, a first-in-class Bispecific T-cell Engager (BiTE) immunotherapy approved in May 2024, generated $215 million in sales in the first half of 2025 and is now expected to reach $2.8 billion by 2035. Bispecific T-cell Engager immunotherapy is a type of engineered antibody-based treatment designed to harness the body’s immune system, specifically T cells, to fight cancer.
▣ BlackRock’s (BLK) ex-dividend date is September 5, and its payment date is September 23.
▣ In its fiscal third quarter, the Bank of Nova Scotia (BNS) delivered a robust performance with adjusted net income of $1.83 billion,1 up from $1.6 billion in the same period a year earlier. This translates to adjusted diluted earnings per share of $1.37, compared to $1.19 previously, and exceeding consensus estimates. The bank reported solid top-line momentum, with net interest income climbing to nearly $4 billion and total revenue reaching $6.9 billion, both reflecting healthy year-over-year gains. Performance was further bolstered by lower-than-expected loan-loss provisions of $0.8 billion, below the anticipated $0.87 billion.
Across business segments, results were broadly positive. Canadian Banking posted a 56% sequential boost in adjusted earnings to $697 million, though slightly lower than the prior year. International Banking delivered a 7% year-over-year increase to $521 million, while Global Wealth Management advanced 13%. The strongest contribution came from Global Banking & Markets, where adjusted earnings surged 29% year-over-year.
Scotiabank ended the quarter with a CET1 capital ratio of 13.3%, underscoring its resilient balance sheet and ability to navigate uncertain economic conditions.
—
1- All the figures have been converted from Canadian dollars to U.S. dollars.
▣ According to a Reuters report, U.S. and Russian officials reportedly discussed incentives, such as ExxonMobil (XOM) re-entering Russia’s Sakhalin-1 oil and gas project, as part of peace talks surrounding Ukraine, contingent on sanctions easing and political progress. In another report, the Wall Street Journal reported that Exxon had held secret talks with Russia’s state energy company Rosneft, exploring its possible return to offshore drilling in Sakhalin, an island in Russia’s Far East.
▣ IBM (IBM) strengthened its leadership across advanced computing domains by announcing a collaboration with AMD to develop quantum-centric supercomputing architectures. The partnership will combine IBM’s progress in quantum hardware and software with AMD’s high-performance CPUs, GPUs, and AI accelerators to create scalable hybrid systems capable of tackling algorithms beyond the reach of either technology alone. The companies are planning an initial demonstration later this year and will leverage open-source platforms like Qiskit to accelerate adoption, reinforcing IBM’s role at the forefront of quantum, AI, and high-performance computing convergence.
In other news, IBM has won a new $18.7 million contract with the Australian Department of Defense as part of its ongoing project to upgrade its ERP system. When combined with two recent amendments to earlier contracts, worth $13 million and $33 million, IBM’s role in the program has increased significantly. Since 2019, the total value of Australian Defense’s ERP work with IBM has now reached at least $575 million.
▣ According to a Reuters report, Kroger (KR) could lay off fewer than 1,000 corporate employees, a strategic move aimed at simplifying organizational structure and refocusing resources on customer-facing areas, such as lowering prices, opening new stores, and creating store-level jobs, without affecting store or warehouse staff.
▣ PepsiCo’s (PEP) ex-dividend date is September 5, and its dividend is payable on September 30.
▣ Qualcomm’s (QCOM) ex-dividend date is September 4, and its dividend is payable on September 25.
1
Recent Trades
None at the moment, although we are considering adding a stock to our portfolio when the market conditions allow for an attractive entry point. Stay tuned.
1
1
Portfolio Attributes
| Dividend Portfolio Yield |
Expected Dividend Growth | Expected Annual Income |
| 4.02% | +6.04% | $6,075.05 |
| Yield-on-Cost Adjusted, Weighted |
Average Analyst 12-Month Growth Outlook | 10K Per Stock at the Time of Purchase |
Current Portfolio
| Name | EX-Dividend Date | Payment Date | Yield on Cost | Annual DPS |
| Automatic Data Processing (ADP) | Sep 12, 2025 | Oct 01, 2025 | 2.46% | $6.16 |
| Amgen (AMGN) | Nov 18, 2025 | Dec 09, 2025 | 3.27% | $9.52 |
| BlackRock (BLK) | Dec 04, 2025 | Dec 23, 2025 | 2.61% | $20.84 |
| Bank of Nova Scotia (BNS) | Oct 02, 2025 | Oct 29, 2025 | 5.98% | $3.2 |
| EOG Resources (EOG) | Oct 17, 2025 | Oct 31, 2025 | 3.06% | $4.08 |
| ExxonMobil (XOM) | Nov 17, 2025 | Dec 10, 2025 | 3.64% | $3.96 |
| IBM (IBM) | Nov 12, 2025 | Dec 10, 2025 | 3.14% | $6.72 |
| JPMorgan Chase (JPM) | Oct 07, 2025 | Oct 31, 2025 | 3.43% | $6.00 |
| Kroger (KR) | Nov 17, 2025 | Dec 01, 2025 | 3.08% | $1.40 |
| LyondellBasell (LYB) | Dec 02, 2025 | Dec 09, 2025 | 5.74% | $5.48 |
| PepsiCo (PEP) | Dec 09, 2025 | Jan 06, 2026 | 3.8% | $5.69 |
| Philip Morris (PM) | Sep 25, 2025 | Oct 09, 2025 | 6.06% | $5.40 |
| Qualcomm (QCOM) | Dec 08, 2025 | Dec 22, 2025 | 2.36% | $3.56 |
| VICI Properties (VICI) | Sep 18, 2025 | Oct 06, 2025 | 5.22% | $1.73 |
| Verizon (VZ) | Oct 09, 2025 | Nov 04, 2025 | 6.09% | $2.71 |
NameEX-Dividend DatePayment DateYield on Cost Annual DPS
1
1
1
Click here for more stock market analysis from TipRanks Macro & Markets research analyst Yulia Vaiman
1
Disclaimer
The information contained in this article represents the views and opinions of the writer only, and not the views or opinions of TipRanks or its affiliates and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy, or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment, and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices, or performance.
